Read This Twitter Chat About Gilead and the Cost of its Hep C Drug

Bloomberg reporter Drew Armstrong has been doing some great reporting on the controversy surrounding Gilead Sciences (GILD) and it's $1,000-a-day hepatitis C pill Sovaldi. The issues has definitely weighed some on Gilead's stock price recently. Armstrong published a new story today discussing how Medicaid providers were limiting access to Sovaldi because of its price. 

The story prompted an excellent discussion between Armstrong and ISI Group analyst Mark Schoenebaum, who's been bullish on Gilead and the Sovaldi launch. Twitter makes it hard to follow long conversation threads, so I stitched it together below:

Yes, Mark, you've earned your Twitter manhood badge today. Well done! 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Adobe Isn't Just Going After Shopify With Its Latest Acquisition

Adobe Isn't Just Going After Shopify With Its Latest Acquisition

Experts Break Down GDPR Risks for Investors

Experts Break Down GDPR Risks for Investors